Benzylpenicillin benzathine powder for suspension for injection defect
Class 4 medicines defect notification: Brancaster Pharma Limited, benzylpenicillin benzathine 1.2 million I.U. and 2.4 million I.U. powder for suspension for injection
Published: 29 June 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification.
Brancaster Pharma Limited reported an error that the patient information leaflet (PIL) in the cartons for specified batches were released with an outdated PIL.
Further information, advice and details of the affected batches can be found on the MHRA website.